<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; LLY</title>
	<atom:link href="http://www.stockbloghub.com/tag/lly/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 19 May 2013 21:00:15 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.5.1</generator>
		<item>
		<title>(LLY) Eli Lilly and Company Sees Positive Data on Diabetes Candidate</title>
		<link>http://www.stockbloghub.com/2013/05/03/lly-eli-lilly-and-company-sees-positive-data-on-diabetes-candidate/133967</link>
		<comments>http://www.stockbloghub.com/2013/05/03/lly-eli-lilly-and-company-sees-positive-data-on-diabetes-candidate/133967#comments</comments>
		<pubDate>Fri, 03 May 2013 17:49:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=133967</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently announced top-line data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in two phase III studies (AWARD-2 and AWARD-4) which are a part of the AWARD program. Dulaglutide is a glucagon-like peptide 1 (GLP-1) analog which is being developed for the once-weekly treatment of type II diabetes. Eli Lilly said that with dulaglutide (1.5 mg) meeting the primary efficacy endpoint of non-inferiority to insulin glargine, superiority for lowering HbA1c levels was also evaluated. Dulaglutide 1.5 mg achieved a statistically superior reduction in HbA1c level compared to insulin glargine at 52 weeks in type II diabetes patients on metformin and glimeperide (AWARD-2). Moreover, results from AWARD-4 showed that dulaglutide 1.5 mg plus insulin lispro demonstrated a statistically ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/05/03/lly-eli-lilly-and-company-sees-positive-data-on-diabetes-candidate/133967/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Pipeline Progress at Alkermes</title>
		<link>http://www.stockbloghub.com/2013/05/02/alks-pipeline-progress-at-alkermes/134214</link>
		<comments>http://www.stockbloghub.com/2013/05/02/alks-pipeline-progress-at-alkermes/134214#comments</comments>
		<pubDate>Thu, 02 May 2013 21:07:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=134214</guid>
		<description><![CDATA[Alkermes (ALKS) recently announced encouraging top-line data from a phase II study (n=142) on ALKS 5461. The study evaluated the safety and efficacy of ALKS 5461 across two doses for the treatment of major depressive disorder (MDD) in patients who did not respond satisfactorily to currently available therapies for clinical depression. Results from the randomized, double-blind, multicenter, placebo-controlled study showed that depressive symptoms were reduced across a range of standard measures. Results also revealed that ALKS 5461 was well tolerated during the study. Alkermes now plans to advance ALKS 5461 into a pivotal development program based on the positive phase II data and previously reported favorable phase I/II results. We note that the MDD market currently has big players like Eli Lilly and Company (LLY) and Pfizer Inc. (PFE). ALKS ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/05/02/alks-pipeline-progress-at-alkermes/134214/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Will Johnson &amp; Johnson Miss on Earnings?</title>
		<link>http://www.stockbloghub.com/2013/04/23/jnj-will-johnson-johnson-miss-on-earnings/133795</link>
		<comments>http://www.stockbloghub.com/2013/04/23/jnj-will-johnson-johnson-miss-on-earnings/133795#comments</comments>
		<pubDate>Tue, 23 Apr 2013 18:08:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=133795</guid>
		<description><![CDATA[Johnson &#38; Johnson (JNJ) is scheduled to report its first quarter 2013 results on Apr 16, 2013 before the opening bell. Last quarter, the company posted a 1.71% positive surprise. Let’s see how things are shaping up prior to the announcement. Factors at Play for 1Q Last quarter, Johnson &#38; Johnson recorded growth on the back of strong product sales despite the negative impact of currency fluctuation. Even though we expect the company to continue facing headwinds in the form of pricing pressure, manufacturing issues and US healthcare reform, we believe Johnson &#38; Johnson’s diversified business model, lack of cyclicality, and strong financial position will continue to help the company pave its way through difficult situations. Earnings Whispers? Our proven model does not conclusively show that Johnson &#38; Johnson is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/04/23/jnj-will-johnson-johnson-miss-on-earnings/133795/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(IBM) Into the Heart of First Quarter Earnings Season &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2013/04/22/ibm-into-the-heart-of-first-quarter-earnings-season-earnings-preview/134472</link>
		<comments>http://www.stockbloghub.com/2013/04/22/ibm-into-the-heart-of-first-quarter-earnings-season-earnings-preview/134472#comments</comments>
		<pubDate>Tue, 23 Apr 2013 05:16:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Computer Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Amazon.com Inc]]></category>
		<category><![CDATA[AMZN]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Coach Inc.]]></category>
		<category><![CDATA[COH]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DFS]]></category>
		<category><![CDATA[DHI]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Discover Financial Services]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[DOW]]></category>
		<category><![CDATA[DR Horton Inc.]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[LUV]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[National Oilwell Varco Incorporated]]></category>
		<category><![CDATA[Netflix Inc.]]></category>
		<category><![CDATA[NFLX]]></category>
		<category><![CDATA[NOV]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[PHM]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[Pulte Homes Inc.]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[QUALCOMM Inc]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[Southwest Airlines Company]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[T. Rowe Price Group Inc.]]></category>
		<category><![CDATA[Texas Instruments Inc.]]></category>
		<category><![CDATA[The Dow Chemical Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[TOT]]></category>
		<category><![CDATA[Total SA]]></category>
		<category><![CDATA[TROW]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TXN]]></category>
		<category><![CDATA[United Parcel Service Inc.]]></category>
		<category><![CDATA[UPS]]></category>
		<category><![CDATA[Westar Energy Inc.]]></category>
		<category><![CDATA[WR]]></category>
		<category><![CDATA[XOM]]></category>
		<category><![CDATA[YUM]]></category>
		<category><![CDATA[Yum! Brands Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=134472</guid>
		<description><![CDATA[There is an air of disappointment in the market about the ongoing Q1 earnings season. Some of it is justified. After all, what else should investors think when companies like IBM (IBM) and GE (GE) come up short? Results from the Technology sector have been underwhelming and the revenues overall have been on the weak side. That said, the reality is that Q1 results aren’t materially weaker than what we saw in the 2012 Q4 earnings season. The market seemed satisfied, if not exactly thrilled, with Q4 results, as its strong momentum in January and February this year shows. What this means is that the excessive hand-wringing may not solely be due to Q1 results, but rather what these results tell us about the coming quarters. Consensus expectations for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/04/22/ibm-into-the-heart-of-first-quarter-earnings-season-earnings-preview/134472/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(IBM) The Market Now Moves Into the Heart of the First Quarter Earnings Season &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2013/04/19/ibm-the-market-now-moves-into-the-heart-of-the-first-quarter-earnings-season-earnings-preview/134289</link>
		<comments>http://www.stockbloghub.com/2013/04/19/ibm-the-market-now-moves-into-the-heart-of-the-first-quarter-earnings-season-earnings-preview/134289#comments</comments>
		<pubDate>Sat, 20 Apr 2013 00:55:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Computer Systems]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Amazon.com Inc]]></category>
		<category><![CDATA[AMZN]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Coach Inc.]]></category>
		<category><![CDATA[COH]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[DD]]></category>
		<category><![CDATA[DFS]]></category>
		<category><![CDATA[DHI]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Discover Financial Services]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[DOW]]></category>
		<category><![CDATA[DR Horton Inc.]]></category>
		<category><![CDATA[EI DuPont de Nemours & Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[LUV]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[National Oilwell Varco Incorporated]]></category>
		<category><![CDATA[Netflix Inc.]]></category>
		<category><![CDATA[NFLX]]></category>
		<category><![CDATA[NOV]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[PHM]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[Pulte Homes Inc.]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[QUALCOMM Inc]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[Southwest Airlines Company]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[T. Rowe Price Group Inc.]]></category>
		<category><![CDATA[Texas Instruments Inc.]]></category>
		<category><![CDATA[The Dow Chemical Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[TOT]]></category>
		<category><![CDATA[Total SA]]></category>
		<category><![CDATA[TROW]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TXN]]></category>
		<category><![CDATA[United Parcel Service Inc.]]></category>
		<category><![CDATA[UPS]]></category>
		<category><![CDATA[Westar Energy Inc.]]></category>
		<category><![CDATA[WR]]></category>
		<category><![CDATA[XOM]]></category>
		<category><![CDATA[YUM]]></category>
		<category><![CDATA[Yum! Brands Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=134289</guid>
		<description><![CDATA[There is an air of disappointment in the market about the ongoing Q1 earnings season. Some of it is justified. After all, what else should investors think when companies like IBM (IBM) and GE (GE) come up short? Results from the Technology sector have been underwhelming and the revenues overall have been on the weak side. That said, the reality is that Q1 results aren’t materially weaker than what we saw in the 2012 Q4 earnings season. The market seemed satisfied, if not exactly thrilled, with Q4 results, as its strong momentum in January and February this year shows. What this means is that the excessive hand-wringing may not solely be due to Q1 results, but rather what these results tell us about the coming quarters. Consensus expectations for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/04/19/ibm-the-market-now-moves-into-the-heart-of-the-first-quarter-earnings-season-earnings-preview/134289/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi/Transgene Inks Immunotherapy Deal</title>
		<link>http://www.stockbloghub.com/2013/04/11/sny-sanofitransgene-inks-immunotherapy-deal/131946</link>
		<comments>http://www.stockbloghub.com/2013/04/11/sny-sanofitransgene-inks-immunotherapy-deal/131946#comments</comments>
		<pubDate>Thu, 11 Apr 2013 23:32:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Capstead Mortgage Corporation]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CMO]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[RMS]]></category>
		<category><![CDATA[Rydex Inverse 2x S&P MidCap 400]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=131946</guid>
		<description><![CDATA[Sanofi (SNY) recently entered into a collaboration Transgene for the production of immunotherapy products and creating of an industrial platform for the same. The platform will include Transgene’s candidates. Sanofi and Transgene, a French biopharmaceutical company, will invest €10 million in the platform, which will be located at the Genzyme Polyclonals site at Lyon, Gerland. The platform will be solely owned by Sanofi. We note that Genzyme Polyclonals site is already engaged in manufacturing polyclonal antibodies for the global markets. The platform possesses the capability to facilitate the registration of immunotherapy candidates in the US and EU. Construction, qualification and validation of the manufacturing facility are expected to commence in the third quarter of 2013. Sanofi expects the first batch of commercial grade drugs to be available in 2015. Under ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/04/11/sny-sanofitransgene-inks-immunotherapy-deal/131946/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Pharma &amp; Biotech Stock Outlook &#8211; Apr 2013 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2013/04/07/mrk-pharma-biotech-stock-outlook-apr-2013-zacks-analyst-interviews/132525</link>
		<comments>http://www.stockbloghub.com/2013/04/07/mrk-pharma-biotech-stock-outlook-apr-2013-zacks-analyst-interviews/132525#comments</comments>
		<pubDate>Sun, 07 Apr 2013 18:52:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AFFY]]></category>
		<category><![CDATA[Affymax Inc]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JAZZ]]></category>
		<category><![CDATA[Jazz Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[OSIR]]></category>
		<category><![CDATA[Osiris Therapeutics Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=132525</guid>
		<description><![CDATA[The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa losing patent protection. These products alone represented branded sales worth more than $15 billion. However, the effect of the genericization of these products was felt mostly in 2012. While the industry won’t be completely free from genericization, the major patent expiries are over and done with. New products should start contributing significantly to results and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector. Some products that are slated to lose patent protection in 2013 include: Collaborations and Acquisitions The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/04/07/mrk-pharma-biotech-stock-outlook-apr-2013-zacks-analyst-interviews/132525/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Announces Positive Drug Approval News</title>
		<link>http://www.stockbloghub.com/2013/03/13/nvs-novartis-announces-positive-drug-approval-news/130279</link>
		<comments>http://www.stockbloghub.com/2013/03/13/nvs-novartis-announces-positive-drug-approval-news/130279#comments</comments>
		<pubDate>Wed, 13 Mar 2013 17:18:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CAPS]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Orthologic Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=130279</guid>
		<description><![CDATA[Novartis (NVS) recently announced that the European Commission (EC) has approved its drug llaris (canakinumab, ACZ885) for an additional indication. The EC cleared llaris for treating adults suffering from gouty arthritis (gout) &#8211; a serious, chronic and progressive inflammatory disease. Patients experience attacks of gout when the body has a strong inflammatory response to the uric acid crystals forming in the affected joint. Moreover, the symptoms of such attacks cannot or should not be managed with existing therapies. Novartis stated in its press release that the approval of Ilaris makes it the first biologic to be cleared in the EU for symptomatic pain relief in a gouty arthritis indication. In addition, Novartis has received an additional year of data exclusivity from the EC, which was determined by the significant clinical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/03/13/nvs-novartis-announces-positive-drug-approval-news/130279/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi Diabetes Drug Under FDA Review</title>
		<link>http://www.stockbloghub.com/2013/03/02/sny-sanofi-diabetes-drug-under-fda-review/128863</link>
		<comments>http://www.stockbloghub.com/2013/03/02/sny-sanofi-diabetes-drug-under-fda-review/128863#comments</comments>
		<pubDate>Sat, 02 Mar 2013 18:47:16 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[RMS]]></category>
		<category><![CDATA[Rydex Inverse 2x S&P MidCap 400]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=128863</guid>
		<description><![CDATA[Sanofi (SNY) recently announced that the US Food and Drug Administration (FDA) has accepted the marketing application of its type II diabetes candidate, lixisenatide. The company is looking to get lixisenatide approved for the treatment of adults with type II diabetes. The company submitted the New Drug Application for lixisenatide on the basis of the GetGoal program. The program initiated in May 2008, consisted of 11 trials and enrolled more than 5,000 type II diabetes patients. Lixisenatide demonstrated a promising efficacy and tolerability profile in the trials. Sanofi had in-licensed lixisenatide from Zealand Pharma. We remind investors that the European Commission (EC) cleared lixisenatide (brand name: Lyxumia in EU) for glycemic control in adults suffering from type II diabetes on Feb 1, 2013. The drug is expected to be launched ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/03/02/sny-sanofi-diabetes-drug-under-fda-review/128863/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) MedTech Industry Stock Outlook &#8211; January 2013 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2013/01/31/jnj-medtech-industry-stock-outlook-january-2013-zacks-analyst-interviews/127562</link>
		<comments>http://www.stockbloghub.com/2013/01/31/jnj-medtech-industry-stock-outlook-january-2013-zacks-analyst-interviews/127562#comments</comments>
		<pubDate>Thu, 31 Jan 2013 19:55:35 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[A]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Agilent Technologies Inc]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson And Company]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[COO]]></category>
		<category><![CDATA[Corning Inc]]></category>
		<category><![CDATA[COV]]></category>
		<category><![CDATA[Covidien plc]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GLW]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HAE]]></category>
		<category><![CDATA[Haemonetics Corporation]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>
		<category><![CDATA[Invacare Corporation]]></category>
		<category><![CDATA[IVC]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Pall Corporation]]></category>
		<category><![CDATA[Patterson Companies Inc.]]></category>
		<category><![CDATA[PDCO]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PLL]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[TER]]></category>
		<category><![CDATA[Teradyne Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[The Cooper Companies Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[XRAY]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=127562</guid>
		<description><![CDATA[We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with almost one-third of the market share. However, emerging economies like Brazil, Russia, India and China – collectively known as the BRICs – are fast coming up in the medical devices space and are attracting a lot of attention. These emerging economies are seeing an increasing uptake of medical devices due largely to growing medical awareness and economic prosperity.  Expansion in emerging markets, especially those with double-digit annual growth rates, represents one of the best potential avenues for growth in 2013 and beyond. On the flip side,  the MedTech industry is currently plagued by several issues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/01/31/jnj-medtech-industry-stock-outlook-january-2013-zacks-analyst-interviews/127562/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARQL) ArQule Shares Fall on Oncology Drug Candidate Setback</title>
		<link>http://www.stockbloghub.com/2013/01/16/arql-arqule-shares-fall-on-oncology-drug-candidate-setback/126240</link>
		<comments>http://www.stockbloghub.com/2013/01/16/arql-arqule-shares-fall-on-oncology-drug-candidate-setback/126240#comments</comments>
		<pubDate>Wed, 16 Jan 2013 23:37:36 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ARQL]]></category>
		<category><![CDATA[ArQule Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Chromcraft Revington Inc]]></category>
		<category><![CDATA[CRC]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=126240</guid>
		<description><![CDATA[ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule’s lead pipeline candidate, tivantinib, in combination with Pfizer’s (PFE) Camptosar (irinotecan) and Bristol-Myers Squibbs/Eli Lilly’s (BMY/LLY) Erbiutx (cetuximab) in patients with refractory or relapsed colorectal cancer (CRC). The study failed to meet its key endpoint of progression-free survival (PFS) &#8211; median PFS was 8.3 months in the tivantinib arm compared with 7.3 months in the control arm (irinotecan and cetuximab plus placebo). The secondary endpoint of objective response rate (ORR) was also not statistically significant compared to the control arm (45% versus 33%). The disappointing news led to an 11.6% decline in the stock price. We note that this is the second setback for ArQule after the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/01/16/arql-arqule-shares-fall-on-oncology-drug-candidate-setback/126240/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk&#8217;s Ryzodeg Approved in Japan</title>
		<link>http://www.stockbloghub.com/2013/01/01/nvo-novo-nordisks-ryzodeg-approved-in-japan/125018</link>
		<comments>http://www.stockbloghub.com/2013/01/01/nvo-novo-nordisks-ryzodeg-approved-in-japan/125018#comments</comments>
		<pubDate>Wed, 02 Jan 2013 00:12:50 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=125018</guid>
		<description><![CDATA[Denmark based Novo Nordisk (NVO) recently announced that it has received approval in Japan for its diabetes treatment, Ryzodeg (insulin degludec/insulin aspart). Ryzodeg was submitted for regulatory approval to the Japanese Ministry of Health, Labour and Welfare in March 2012. Ryzodeg is a soluble formulation of Tresiba (insulin degludec) and NovoRapid (insulin aspart – known as NovoLog in the US). Studies supporting the new drug application revealed that Ryzodeg demonstrated a significantly lower risk of nocturnal hypoglycaemia while successfully achieving equivalent reductions in HbA1c vis-à-vis NovoMix. We note that Tresiba, which is currently under regulatory review in the EU and the US, was approved in Japan in September 2012. Both Tresiba and Ryzodeg received positive opinions from the Committee for Medicinal Products for Human Use (CHMP) in the EU in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2013/01/01/nvo-novo-nordisks-ryzodeg-approved-in-japan/125018/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics Shares Upgraded to Outperform</title>
		<link>http://www.stockbloghub.com/2012/12/24/mygn-myriad-genetics-shares-upgraded-to-outperform/124326</link>
		<comments>http://www.stockbloghub.com/2012/12/24/mygn-myriad-genetics-shares-upgraded-to-outperform/124326#comments</comments>
		<pubDate>Mon, 24 Dec 2012 16:23:54 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merit Medical Systems Inc]]></category>
		<category><![CDATA[MMSI]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[Resmed Inc]]></category>
		<category><![CDATA[RMD]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=124326</guid>
		<description><![CDATA[Following a strong first quarter result and an encouraging guidance, we upgrade our recommendation on Myriad Genetics (MYGN), provider of molecular diagnostic products, to Outperform with a target price of $33. Myriad started fiscal 2013 on a cheery note with 24% year over year growth in earnings per share to 36 cents, beating the Zacks Consensus Estimate of 32 cents. Total revenues surged 21% year over year to $133.4 million, sailing past the Zacks Consensus Estimate of $130 million. Growth was led by Myriad’s flagship product, Bracanalysis (78.7% of total revenues), which witnessed 17% year-over-year growth to gross $105 million in the first quarter. Moreover, the BART (Bracanalysis Rearrangement Technology) test is gaining traction. Revenues from BART test jumped 188% year over year to $7.6 million in the quarter. Additionally, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/24/mygn-myriad-genetics-shares-upgraded-to-outperform/124326/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Ties Up with GE Healthcare</title>
		<link>http://www.stockbloghub.com/2012/12/23/mrk-merck-ties-up-with-ge-healthcare/124153</link>
		<comments>http://www.stockbloghub.com/2012/12/23/mrk-merck-ties-up-with-ge-healthcare/124153#comments</comments>
		<pubDate>Sun, 23 Dec 2012 16:42:18 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=124153</guid>
		<description><![CDATA[Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) imaging agent [18F (flutemetamol)] in the development of Merck’s Alzheimer’s disease candidate, MK-8931. Merck and GE Healthcare are looking to use [18F] flutemetamol to measure beta amyloid deposits in the brain – this would assist in determining the stage of Alzheimer’s disease and disease progression. GE Healthcare will provide [18F] flutemetamol under the collaboration, license and supply agreement. Merck intends to use [18F] flutemetamol as a companion diagnostic tool that will help identify patients for studies that will be conducted with MK-8931. Merck recently moved MK-8931 into a phase II/III study (EPOCH). The study is evaluating the safety and efficacy of MK-8931, an oral ?-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, in mild-to-moderate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/23/mrk-merck-ties-up-with-ge-healthcare/124153/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CHMP) Isis Pharmaceuticals&#8217; Kynamro Earns Negative Report From European Medicines Agency</title>
		<link>http://www.stockbloghub.com/2012/12/19/chmp-isis-pharmaceuticals-kynamro-earns-negative-report-from-european-medicines-agency/123918</link>
		<comments>http://www.stockbloghub.com/2012/12/19/chmp-isis-pharmaceuticals-kynamro-earns-negative-report-from-european-medicines-agency/123918#comments</comments>
		<pubDate>Wed, 19 Dec 2012 17:54:05 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=123918</guid>
		<description><![CDATA[The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently did not recommend the approval of Isis Pharmaceuticals Inc. (ISIS) and partner Genzyme’s, a Sanofi (SNY) company, candidate Kynamro (mipomersen). The companies are seeking US Food and Drug Adminstration (FDA) approval for the use of Kynamro for the treatment of patients with homozygous familial hypercholesterolemia (HoFH). Sanofi is working on getting the negative CHMP decision re-examined and expects to have a final opinion in the second quarter of 2013. We note that the regulatory path of Kynamro has been quite the opposite in the US. In October 2012, the US Food and Drug Administration’s (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted in favor of approving Kynamro. The panel voted 9 to 6 that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/19/chmp-isis-pharmaceuticals-kynamro-earns-negative-report-from-european-medicines-agency/123918/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WPI) An End to Drug Patent Woes?</title>
		<link>http://www.stockbloghub.com/2012/12/16/wpi-an-end-to-drug-patent-woes/123570</link>
		<comments>http://www.stockbloghub.com/2012/12/16/wpi-an-end-to-drug-patent-woes/123570#comments</comments>
		<pubDate>Mon, 17 Dec 2012 03:50:45 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=123570</guid>
		<description><![CDATA[The US Supreme Court will soon hear a case which will determine whether “pay-for-delay&#8221; agreements between drug manufacturers violate anti-trust legislations. These “reverse payment” agreements enable patent holders to pay generic drug manufacturers to delay the launch of generic versions of their drugs. This runs contrary to normal practice, where patent holders sue violators and then seek damages, in some cases through an out of court settlement. The companies standing to benefit in this case were Watson Pharmaceuticals, Inc. (WPI), Paddock Pharmaceuticals – now owned by Perrigo Co. (PRGO) – and Par Pharmaceuticals, Inc. – which was acquired this year by private equity firm TPG Capital. Solvay Pharmaceuticals Inc, now owned by Abbot Laboratories (ABT), was paying them to delay launch of a competing drug. These companies received annual payments ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/16/wpi-an-end-to-drug-patent-woes/123570/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals and AstraZeneca Ink Deal</title>
		<link>http://www.stockbloghub.com/2012/12/16/isis-isis-pharmaceuticals-and-astrazeneca-ink-deal/123605</link>
		<comments>http://www.stockbloghub.com/2012/12/16/isis-isis-pharmaceuticals-and-astrazeneca-ink-deal/123605#comments</comments>
		<pubDate>Mon, 17 Dec 2012 03:43:11 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=123605</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) and AstraZeneca (AZN) recently announced that they have entered into an agreement to discover and develop five new generation antisense oncology drugs, including ISIS-STAT3Rx. ISIS-STAT3Rx is being developed for advanced lymphomas patients. In October 2012, Isis Pharma had reported preliminary results from a dose escalation phase I study of ISIS-STAT3Rx. The candidate demonstrated encouraging efficacy in treatment-refractory advanced cancer patient and a promising safety profile. Currently, a phase II trial is ongoing in patients with advanced lymphomas. As per the terms of the agreement, Isis Pharma will receive upfront and near-term payments of $31 million ($25 million on the signing of the agreement and $6 million in the second quarter of 2013) from AstraZeneca. AstraZeneca will also undertake all the development and commercialization responsibilities of ISIS-STAT3Rx ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/16/isis-isis-pharmaceuticals-and-astrazeneca-ink-deal/123605/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck&#8217;s Alzheimer&#8217;s Drug Progresses</title>
		<link>http://www.stockbloghub.com/2012/12/11/mrk-mercks-alzheimers-drug-progresses/123287</link>
		<comments>http://www.stockbloghub.com/2012/12/11/mrk-mercks-alzheimers-drug-progresses/123287#comments</comments>
		<pubDate>Tue, 11 Dec 2012 18:03:15 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=123287</guid>
		<description><![CDATA[Merck (MRK) recently moved its Alzheimer’s disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will evaluate the safety and efficacy of MK-8931, an oral ?-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, in mild-to-moderate Alzheimer&#8217;s disease patients. Three oral doses of MK-8931 will be compared to placebo in the 78-week, randomized, placebo-controlled, parallel-group, double-blind study. The safety profile of the candidate will be evaluated in 200 patients before phase III studies are initiated. We view MK-8931 as a high risk-high return candidate for Merck. The successful development of therapies for the treatment of Alzheimer’s disease is challenging and we note that several companies have failed in developing treatments for the same. Companies like Eli Lilly (LLY), Pfizer (PFE) and Johnson &#38; Johnson (JNJ) have all faced setbacks in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/11/mrk-mercks-alzheimers-drug-progresses/123287/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Pharmaceuticals and Biotech Stock Outlook &#8211; December 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/12/07/mrk-pharmaceuticals-and-biotech-stock-outlook-december-2012-industry-outlook/122969</link>
		<comments>http://www.stockbloghub.com/2012/12/07/mrk-pharmaceuticals-and-biotech-stock-outlook-december-2012-industry-outlook/122969#comments</comments>
		<pubDate>Fri, 07 Dec 2012 22:19:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BioSpecifics Technologies Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[BSTC]]></category>
		<category><![CDATA[Catalyst Pharmaceutical Partners Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CPRX]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GAIN]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Gladstone Investment Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JAZZ]]></category>
		<category><![CDATA[Jazz Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRX]]></category>
		<category><![CDATA[W&T Offshore Inc]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[WTI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=122969</guid>
		<description><![CDATA[The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa losing patent protection. These products alone represented branded sales worth more than $15 billion. However, the effect of the genericization of these products will be felt mostly in 2012. While the industry won’t be completely free from genericization, the major patent expiries are over and done with. New products should start contributing significantly to results and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector. M&#38;A Activity The M&#38;A activity witnessed in the pharma sector in the last couple of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/07/mrk-pharmaceuticals-and-biotech-stock-outlook-december-2012-industry-outlook/122969/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi&#8217;s Lyxumia Gets Approval From Committee for Medicinal Products for Human Use</title>
		<link>http://www.stockbloghub.com/2012/12/03/sny-sanofis-lyxumia-gets-approval-from-committee-for-medicinal-products-for-human-use/121225</link>
		<comments>http://www.stockbloghub.com/2012/12/03/sny-sanofis-lyxumia-gets-approval-from-committee-for-medicinal-products-for-human-use/121225#comments</comments>
		<pubDate>Mon, 03 Dec 2012 16:09:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Regeneron Pharmaceuticals Inc]]></category>
		<category><![CDATA[REGN]]></category>
		<category><![CDATA[RMS]]></category>
		<category><![CDATA[Rydex Inverse 2x S&P MidCap 400]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=121225</guid>
		<description><![CDATA[Sanofi (SNY) recently announced that the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of its diabetes candidate, Lyxumia (lixisenatide). Sanofi is looking to get Lyxumia approved for glycemic control in patients with type II diabetes, who are above 18 years, in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with lifestyle management, do not provide adequate glycemic control. The European Commission (EC) is expected to take a final decision on Lyxumia in the next 2 to 3 months. The company plans to file for US approval in December 2012. The CHMP rendered a positive opinion on Lyxumia on the basis of the GetGoal phase III program. The GetGoal program was initiated in May 2008 and consisted of 11 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/12/03/sny-sanofis-lyxumia-gets-approval-from-committee-for-medicinal-products-for-human-use/121225/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca&#8217;s Forxiga Gets EU Approval</title>
		<link>http://www.stockbloghub.com/2012/11/15/azn-astrazenecas-forxiga-gets-eu-approval/120753</link>
		<comments>http://www.stockbloghub.com/2012/11/15/azn-astrazenecas-forxiga-gets-eu-approval/120753#comments</comments>
		<pubDate>Thu, 15 Nov 2012 17:41:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=120753</guid>
		<description><![CDATA[Recently, AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that their type II diabetes candidate, Forxiga (dapagliflozin) has received European approval. The European Commission (EC) approved the once-daily oral product for improving glycemic control in type II diabetes patients above 18 years along with lifestyle management and other glucose-lowering products, such as insulin. Forxiga can be used as a monotherapy in patients who are intolerant to metformin. The EU approval did not come as a surprise as earlier in April 2012 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a positive opinion regarding the approval of Forxiga in the EU. We note that the regulatory path for Forxiga has been quite diverse as far as approval in the US and EU is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/11/15/azn-astrazenecas-forxiga-gets-eu-approval/120753/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WMT) Stock Market News for October 16, 2012 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2012/10/16/wmt-stock-market-news-for-october-16-2012-market-news/116404</link>
		<comments>http://www.stockbloghub.com/2012/10/16/wmt-stock-market-news-for-october-16-2012-market-news/116404#comments</comments>
		<pubDate>Wed, 17 Oct 2012 04:59:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Discount Variety Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BIG]]></category>
		<category><![CDATA[Big Lots Inc.]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PriceSmart Inc]]></category>
		<category><![CDATA[PSMT]]></category>
		<category><![CDATA[Sears Holdings Corporation]]></category>
		<category><![CDATA[SHLD]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WMT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=116404</guid>
		<description><![CDATA[Strong September retail sales data coupled with better-than-expected quarterly results by Citigroup drove the benchmarks into the positive territory yesterday. The positive tone helped benchmarks to rebound from its previous week’s losses and guided Dow to register its biggest gain in one month. Financial sectors and health care sectors were the major gainers yesterday. However, investors remained watchful about Spain’s bailout. The Dow Jones Industrial Average (DJI) rose 0.7% to close the day at 13,424.23. The Standard &#38; Poor 500 (S&#38;P 500) climbed 0.8% to finish yesterday’s trading session at 1,440.13. The tech-laden Nasdaq Composite Index surged 0.7% to end at 3,064.18. The fear-gauge CBOE Volatility Index (VIX) was down by 5.4% to settle at 15.27. Consolidated volumes on the New York Stock Exchange, American Stock Exchange and Nasdaq were ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/10/16/wmt-stock-market-news-for-october-16-2012-market-news/116404/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly and Company&#8217;s Cialis Gets Opinion From Committee for Medicinal Products for Human Use</title>
		<link>http://www.stockbloghub.com/2012/10/09/lly-eli-lilly-and-companys-cialis-gets-opinion-from-committee-for-medicinal-products-for-human-use/113747</link>
		<comments>http://www.stockbloghub.com/2012/10/09/lly-eli-lilly-and-companys-cialis-gets-opinion-from-committee-for-medicinal-products-for-human-use/113747#comments</comments>
		<pubDate>Tue, 09 Oct 2012 18:50:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[Consolidated Edison Inc.]]></category>
		<category><![CDATA[ED]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=113747</guid>
		<description><![CDATA[Eli Lilly and Company’s (LLY) Cialis (tadalafil) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP issued an opinion in favor of approving Eli Lilly’s erectile dysfunction (ED) drug, Cialis (5 mg), for the once-daily treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). A response from the European Commission regarding Cialis’ regulatory status should be out in two months. The CHMP’s opinion was based on a review of safety and efficacy data on 1,500 patients from four clinical studies of BPH, including a study of BPH and ED. Cialis’ label expansion would provide patients suffering from both ED and BPH with a new treatment option. Approval for the additional indication will help boost ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/10/09/lly-eli-lilly-and-companys-cialis-gets-opinion-from-committee-for-medicinal-products-for-human-use/113747/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Suffers Pipeline Setback</title>
		<link>http://www.stockbloghub.com/2012/08/24/amgn-amgen-suffers-pipeline-setback/108392</link>
		<comments>http://www.stockbloghub.com/2012/08/24/amgn-amgen-suffers-pipeline-setback/108392#comments</comments>
		<pubDate>Fri, 24 Aug 2012 17:44:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[DMC]]></category>
		<category><![CDATA[Document Security Systems Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=108392</guid>
		<description><![CDATA[Amgen (AMGN) recently suffered a pipeline setback with the company deciding to halt the development of its oncology candidate, ganitumab (AMG 479).The decision was based on the recommendation of an independent Data Monitoring Committee (DMC). The randomized, multicenter, double-blind, phase III study (GAMMA) evaluated whether the combination of AMG479 and Eli Lilly’s (LLY) Gemzar improved overall survival in patients suffering from metastatic adenocarcinoma of the pancreas versus placebo and Gemzar, as a first-line therapy. However, after conducting a pre-planned interim analysis of the data, the DMC concluded that the combination of AMG479 and Gemzar would not be likely to improve the survival in patients compared to Gemzar plus placebo. However, the DMC’s analysis of the data from the phase III study did not raise any safety concern(s). In addition to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/24/amgn-amgen-suffers-pipeline-setback/108392/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pfizer and Johnson &amp; Johnson End Bapineuzumab IV</title>
		<link>http://www.stockbloghub.com/2012/08/21/pfe-pfizer-and-johnson-johnson-end-bapineuzumab-iv/107780</link>
		<comments>http://www.stockbloghub.com/2012/08/21/pfe-pfizer-and-johnson-johnson-end-bapineuzumab-iv/107780#comments</comments>
		<pubDate>Tue, 21 Aug 2012 21:08:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AIP]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Hadera Paper Limited]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=107780</guid>
		<description><![CDATA[Pfizer, Inc. (PFE) recently announced disappointing late-stage results on intravenous (IV) bapineuzumab. Bapineuzumab is being developed under Pfizer and Johnson &#38; Johnson’s (JNJ) Janssen Alzheimer Immunotherapy R&#38;D LLC&#8217;s Alzheimer’s Immunotherapy Program (AIP). Pfizer and Janssen AI are partners in AIP and Elan Corporation (ELN) has a 49.9% interest in Janssen AI following its September 2009 transaction with Johnson &#38; Johnson. Pfizer said that bapineuzumab failed to meet the co-primary endpoints in a phase III study (Study 301) being conducted in mild-to-moderate Alzheimer’s disease patients who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype. This is the second set of disappointing data to be presented on bapineuzumab over the last few weeks. On July 23, Pfizer had announced that bapineuzumab failed to meet its co-primary endpoints in a phase ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/21/pfe-pfizer-and-johnson-johnson-end-bapineuzumab-iv/107780/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Earnings Preview</title>
		<link>http://www.stockbloghub.com/2012/08/13/bmy-bristol-myers-squibb-earnings-preview/105439</link>
		<comments>http://www.stockbloghub.com/2012/08/13/bmy-bristol-myers-squibb-earnings-preview/105439#comments</comments>
		<pubDate>Mon, 13 Aug 2012 13:35:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=105439</guid>
		<description><![CDATA[Biopharmaceutical giant  Bristol-Myers Squibb Company (BMY) is all set to unveil  its second quarter 2012 results before the start of trading on July 25, 2012. The Zacks Consensus Estimate for the second quarter of 2012 is 50 cents (year-over-year decrease of 10.7%) on revenues of $4,460 million (year-over-year decrease of 17.9%). First Quarter Recap Bristol-Myers’ first quarter 2012 earnings (excluding special items) of 64 cents per share beat the Zacks Consensus Estimate of 61 cents. First quarter earnings increased 10% from the year-ago period. Strong revenues aided earnings in the reported quarter. Newly launched products did very well during the quarter. Net sales in the reported quarter climbed 5% to $5.25 billion. Revenues were just shy of the Zacks Consensus Estimate of $5.26 billion, mainly due to lower sales of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/13/bmy-bristol-myers-squibb-earnings-preview/105439/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFE) Pharma and Biotech Stock Outlook &#8211; August 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/08/10/pfe-pharma-biotech-stock-outlook-august-2012-industry-outlook/108031</link>
		<comments>http://www.stockbloghub.com/2012/08/10/pfe-pharma-biotech-stock-outlook-august-2012-industry-outlook/108031#comments</comments>
		<pubDate>Fri, 10 Aug 2012 18:00:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Allos Therapeutics Inc.]]></category>
		<category><![CDATA[ALTH]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Cardiome Pharma Corporation]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CRME]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GAIN]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Gladstone Investment Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Optimer Pharmaceuticals Inc]]></category>
		<category><![CDATA[OPTR]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Spectrum Pharmaceuticals Inc.]]></category>
		<category><![CDATA[SPPI]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[United Therapeutics Corporation]]></category>
		<category><![CDATA[UTHR]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=108031</guid>
		<description><![CDATA[The pharmaceutical industry is in the midst of one of the biggest patent cliffs with Pfizer’s (PFE) multi-billion-dollar blockbuster drug Lipitor losing patent protection in the US in late November 2011. Besides Lipitor, other major branded drugs that lost patent protection in the past few months include Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa. These products alone represented branded sales worth more than $15 billion. Another product that will start facing generic competition shortly is Merck’s (MRK) blockbuster Singulair. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. While generics will eat into sales, new products are not expected to generate the same level of sales as products losing patent protection. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/08/10/pfe-pharma-biotech-stock-outlook-august-2012-industry-outlook/108031/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) Good News for AstraZeneca</title>
		<link>http://www.stockbloghub.com/2012/07/17/azn-good-news-for-astrazeneca/104734</link>
		<comments>http://www.stockbloghub.com/2012/07/17/azn-good-news-for-astrazeneca/104734#comments</comments>
		<pubDate>Tue, 17 Jul 2012 17:09:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Central Vermont Public Service Corporation]]></category>
		<category><![CDATA[CV]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDCO]]></category>
		<category><![CDATA[Medicines Company]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[UA]]></category>
		<category><![CDATA[Under Armour Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=104734</guid>
		<description><![CDATA[Good news flowed in at AstraZeneca (AZN) with the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) panel of experts updating their guidelines and issuing a class 1 recommendation for Brilinta (ticagrelor). The class 1 recommendation was issued for the use of Brilinta in invasively and non-invasively managed patients suffering from unstable angina (UA) or non–ST-elevation myocardial infarction (NSTEMI). We note that anti-platelet Brilinta has received the highest recommendation issued by the guidelines committee. We believe that this will encourage physicians to prescribe Brilinta and provide a much needed boost to Brilinta sales. Brilinta is approved for reducing the rate of heart attack and cardiovascular (CV) events in adult patients with acute coronary syndrome (ACS) including UA, NSTEMI and ST-elevation myocardial infarction (STEMI). Brilinta was approved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/07/17/azn-good-news-for-astrazeneca/104734/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PFS) Merck KGaA&#8217;s Erbitux Drug Disappoints in Trial</title>
		<link>http://www.stockbloghub.com/2012/07/11/pfs-merck-kgaas-erbitux-drug-disappoints-in-trial/104254</link>
		<comments>http://www.stockbloghub.com/2012/07/11/pfs-merck-kgaas-erbitux-drug-disappoints-in-trial/104254#comments</comments>
		<pubDate>Wed, 11 Jul 2012 14:32:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Savings & Loans]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PFS]]></category>
		<category><![CDATA[Provident Financial Services Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=104254</guid>
		<description><![CDATA[Merck KGaA (MKGAF) recently announced that Erbitux failed to achieve its primary endpoint in the phase III EXPAND trial, conducted in patients with advanced gastric cancer. Results showed that Erbitux plus cisplatin and capecitabine failed to significantly increase progression-free survival (PFS) in patients with advanced gastric cancer. Earlier in May 2012, Merck KGaA had presented disappointing interim results on Erbitux from a phase III study &#8211; PETACC-81. Results from the study revealed that Erbitux, when given in combination with standard chemotherapy (FOLFOX 4), did not prolong disease-free survival in patients, as compared to those treated with FOLFOX 4 alone. Erbitux is currently marketed in the US and EU for colorectal cancer and squamous cell cancer of the head and neck. The product is under review in the EU for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/07/11/pfs-merck-kgaas-erbitux-drug-disappoints-in-trial/104254/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen&#8217;s KRAS Test Earns U.S. Food and Drug Administration Nod</title>
		<link>http://www.stockbloghub.com/2012/07/09/qgen-qiagens-kras-test-earns-u-s-food-and-drug-administration-nod/104070</link>
		<comments>http://www.stockbloghub.com/2012/07/09/qgen-qiagens-kras-test-earns-u-s-food-and-drug-administration-nod/104070#comments</comments>
		<pubDate>Mon, 09 Jul 2012 16:08:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=104070</guid>
		<description><![CDATA[Molecular diagnostics solutions provider, Qiagen (QGEN) recently got the nod of the U.S. Food and Drug Administration (“FDA”) to market the therascreen KRAS RGQ PCR Kit (therascreen KRAS test), which helps in determining the responsiveness of the metastatic colorectal cancer patients to the drug Erbitux (cetuximab). Qiagen considers this FDA approval of the therascreen KRAS test as a major breakthrough in the company’s international expansion of its Personalized Healthcare franchise that comprises a huge portfolio of molecular companion diagnostics to guide treatments in oncology. The drug Erbitux is an epidermal growth factor receptor (EGFR) inhibitor and is used to treat colon and rectum cancer. It is also beneficial for head and neck cancer treatment. Currently, this drug is marketed in the U.S. by Bristol-Myers Squibb Co. (BMY) and Eli Lilly ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/07/09/qgen-qiagens-kras-test-earns-u-s-food-and-drug-administration-nod/104070/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly and Company GLP-1 Agonist Delivers</title>
		<link>http://www.stockbloghub.com/2012/05/28/lly-eli-lilly-and-company-glp-1-agonist-delivers/100867</link>
		<comments>http://www.stockbloghub.com/2012/05/28/lly-eli-lilly-and-company-glp-1-agonist-delivers/100867#comments</comments>
		<pubDate>Mon, 28 May 2012 14:41:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[DBP]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[PowerShares DB Precious Metals]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Santander Bancorp]]></category>
		<category><![CDATA[SBP]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=100867</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently presented positive phase II data on its type II diabetes candidate, dulaglutide. The company said that dulaglutide met its primary endpoint in the study. Dulaglutide is a glucagon-like peptide 1 (GLP-1) analog which is being developed for the once-weekly treatment of type II diabetes. Results from the phase II, randomized, double-blind, placebo-controlled, 26-week, parallel study showed that dulaglutide achieved non-inferiority after 16 weeks for mean 24-hour systolic blood pressure (SBP). Two doses (0.75 mg and 1.5 mg) of dulaglutide were evaluated in comparison to placebo. With the primary endpoint of non-inferiority being achieved, superiority testing was conducted. Eli Lilly said that the 1.5 mg dose achieved a statistically significant reduction in mean 24-hour SBP compared to placebo. Results at week 26 were similar. Meanwhile, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/05/28/lly-eli-lilly-and-company-glp-1-agonist-delivers/100867/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Active on the Generics Front</title>
		<link>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937</link>
		<comments>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937#comments</comments>
		<pubDate>Mon, 09 Apr 2012 18:03:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Dr. Reddy's Laboratories Limited]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RDY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97937</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro. While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel. As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively. Teva also launched its authorized generic of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/09/teva-teva-pharmaceutical-industries-active-on-the-generics-front/97937/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Healthcare Reform: Bad News for Big Pharma?</title>
		<link>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425</link>
		<comments>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:56:03 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97425</guid>
		<description><![CDATA[Healthcare reform could be a minefield for Big Pharma in the long run. The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case. In an effort to figure out which way the vote was going to swing, the media analyzed every word, pause and twitch the justices made. Though all of that heavy-duty analysis doesn’t actually prove anything; while the Court has likely already decided the healthcare mandate’s fate one way or the other, “We the People” probably won’t find out until June. Considering the political left’s repeated complaints about Solicitor General Donald Verrilli Jr. and Deputy Attorney General Edwin S. Kneedler’s admittedly painful performance in explaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Earns Positive News on Pipeline</title>
		<link>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441</link>
		<comments>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441#comments</comments>
		<pubDate>Tue, 06 Mar 2012 21:31:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94441</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) recently reported back-to-back positive news on the pipeline front. The company and partner Gedeon Richter Plc. announced that their late-stage anti-psychotic candidate, cariprazine, met its primary endpoint in two phase III studies. The studies were conducted to evaluate cariprazine for the treatment of acute exacerbation of schizophrenia. Results showed that patients in the cariprazine arm achieved a significant improvement in symptom compared to patients in the placebo arm. Statistically significant separation from placebo was observed in all doses from week 2 and at each subsequent time point. Forest Labs and Gedeon said that the higher dose showed separation as early as week 1 of treatment.  The results were similar to data presented earlier from a phase IIb fixed-dose placebo-controlled study. Cariprazine is one of the candidates ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/06/frx-forest-laboratories-earns-positive-news-on-pipeline/94441/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(FRX) Forest Laboratories Learns of Positive Results on Gedeon Drug</title>
		<link>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536</link>
		<comments>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536#comments</comments>
		<pubDate>Tue, 14 Feb 2012 04:54:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MDD]]></category>
		<category><![CDATA[SPDR S&P International Mid Cap]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91536</guid>
		<description><![CDATA[Forest Laboratories, Inc. (FRX) and partner Gedeon Richter recently presented positive top-line results on their antipsychotic candidate, cariprazine (RGH-188). Preliminary top-line results were presented from a phase III study that was conducted in patients with acute mania associated with bipolar I disorder. Results from the five-week multi-center, double-blind, placebo-controlled, parallel-group study showed that patients in the cariprazine arm experienced significant symptom improvement compared to patients in the placebo arm. The improvement was observed as early as the fifth day of treatment and at each subsequent time point studied. Cariprazine, a novel, orally active D2/D3 antagonist, was generally well tolerated. However, discontinuations due to adverse events were higher in the cariprazine arms compared to placebo. Forest Labs intends to analyze the data further. Results from this study were similar to those ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/13/frx-forest-laboratories-learns-of-positive-results-on-gedeon-drug/91536/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Posts Lower Loss</title>
		<link>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689</link>
		<comments>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689#comments</comments>
		<pubDate>Tue, 25 Oct 2011 17:38:34 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[iShares S&P Target Date 2010]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NICE Systems Limited]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TZD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85689</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 7 cents per share in the third quarter of 2011, well below the Zacks Consensus Estimate of a loss of 15 cents and the year-ago loss of 31 cents. Higher revenues and lower expenses led to the lower year-over-year loss. Third quarter revenues, which included a $15 million milestone payment, increased 12.1% to $175 million. Revenues exceeded the Zacks Consensus Estimate of $166 million. Quarterly Details Quarterly revenues consisted of $155.1 million in product sales (up 0.7%) and $19.9 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Collaborative revenues included a $15 million milestone payment from Lilly on the launch of Bydureon in the EU. Collaborative ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/25/amln-amylin-pharmaceuticals-posts-lower-loss/85689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) A Busy Week Ahead &#8211; Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152</link>
		<comments>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152#comments</comments>
		<pubDate>Mon, 17 Oct 2011 15:31:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Access National Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Alliance Financial Corporation]]></category>
		<category><![CDATA[ALNC]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[American River Bankshares]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMRB]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[AN]]></category>
		<category><![CDATA[ANCX]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[APOL]]></category>
		<category><![CDATA[Apollo Group Inc.]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[AutoNation Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBND]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BGG]]></category>
		<category><![CDATA[BigBand Networks Inc]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[Bottomline Technologies Inc]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[Briggs & Stratton Corporation]]></category>
		<category><![CDATA[BRKL]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brookline Bancorp Inc]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Buffalo Wild Wings Inc.]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BWLD]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Capital One Financial Corporation]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CKH]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[COF]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Community Trust Bancorp Inc]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[CREE]]></category>
		<category><![CDATA[Cree Inc.]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTBI]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Diamondrock Hospitality Company]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[Dominos Pizza Inc.]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DPZ]]></category>
		<category><![CDATA[DRH]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[ENZ]]></category>
		<category><![CDATA[Enzo Biochem Inc]]></category>
		<category><![CDATA[EPAY]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[F.N.B. Corporation]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIN]]></category>
		<category><![CDATA[FHN]]></category>
		<category><![CDATA[Fidelity National Financial Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Financial Bankshares Inc]]></category>
		<category><![CDATA[First Horizon National Corporation]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flexsteel Industries Inc]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FLXS]]></category>
		<category><![CDATA[FNB]]></category>
		<category><![CDATA[FNF]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FSI International Inc]]></category>
		<category><![CDATA[FSII]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GATX Corporation]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GHL]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[GMT]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[Greenhill & Co Inc.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HA]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[HAR]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[Harman International Industries Inc]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[Hawaiian Holdings Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[HCBK]]></category>
		<category><![CDATA[HCCI]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[Heritage-Crystal Clean Inc]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[HUBB]]></category>
		<category><![CDATA[Hubbell Inc B Shares]]></category>
		<category><![CDATA[Hudson City Bancorp Inc]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INDB]]></category>
		<category><![CDATA[Independent Bank Corporation]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNPR]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Journal Communications Inc.]]></category>
		<category><![CDATA[JRN]]></category>
		<category><![CDATA[Juniper Networks Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[Kensey Nash Corporation]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[Knight Transportation Inc]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KNSY]]></category>
		<category><![CDATA[KNX]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[Koninklijke Philips Electronics NV]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Lakeland Bancorp Inc]]></category>
		<category><![CDATA[Lam Research Corporation]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LBAI]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Linear Technology Corporation]]></category>
		<category><![CDATA[LLTC]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LRCX]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[LUV]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Mattson Technology Inc]]></category>
		<category><![CDATA[Maxim Integrated Products Inc]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHP]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MNI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MTSN]]></category>
		<category><![CDATA[MXIM]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NBL]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[Noble Energy Inc]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OKSB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORB]]></category>
		<category><![CDATA[Orbital Sciences Corporation]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[Parker Hannifin Corporation]]></category>
		<category><![CDATA[Patni Computer Systems Limited]]></category>
		<category><![CDATA[Patriot Coal Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCX]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PFBC]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[PH]]></category>
		<category><![CDATA[PHG]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[Pixelworks Inc]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Preferred Bank]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTI]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[PXLW]]></category>
		<category><![CDATA[Rambus Inc.]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[RCKY]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RMBS]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[ROC]]></category>
		<category><![CDATA[Rockwood Holdings Inc.]]></category>
		<category><![CDATA[Rocky Brands Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[Safe Bulkers Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SB]]></category>
		<category><![CDATA[SBCF]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[SCHN]]></category>
		<category><![CDATA[Schnitzer Steel Industries Inc]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCL]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seacoast Banking Corporation of Florida]]></category>
		<category><![CDATA[Seacor Holdings Inc.]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Shaw Communications Inc.]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[SIVB]]></category>
		<category><![CDATA[SJR]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[SONC]]></category>
		<category><![CDATA[Sonic Corporation]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[Southwest Airlines Company]]></category>
		<category><![CDATA[Southwest Bancorp Inc]]></category>
		<category><![CDATA[Spartan Stores Inc.]]></category>
		<category><![CDATA[SPTN]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Stepan Company]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SUPERVALU Inc.]]></category>
		<category><![CDATA[SVB Financial Group]]></category>
		<category><![CDATA[SVU]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[SYNA]]></category>
		<category><![CDATA[Synaptics Inc]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Tempur Pedic International Inc]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The McClatchy Company]]></category>
		<category><![CDATA[The McGraw-Hill Companies Inc]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[TPX]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[Travelzoo Inc.]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[TZOO]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNF]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[UniFirst Corporation]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USA Truck Inc.]]></category>
		<category><![CDATA[USAK]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[USG]]></category>
		<category><![CDATA[USG Corporation]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[Valley National Bancorp]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[Viad Corporation]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[VLY]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VVI]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Washington Federal Inc]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WD-40 Company]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[WDFC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WFSL]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85152</guid>
		<description><![CDATA[Earnings Preview 10/14/11 While the earnings season kicked off this past week, only 38 firms reported. The game really gets under way next week, when we will get reports from 336 firms, including 99 members of the S&#38;P 500. Thus, by the end of the week we will have a very good idea of how the overall season will go. Not only will there be a lot of reports, but many of those we get will be very important ones. The table at the end of this report reads like a who’s who of American industry, including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Citigroup (C), General Electric (GE), Goldman Sachs (GS), IBM (IBM), Intel (INTC) and McDonald’s (MCD). And that&#8217;s just the first half of the alphabet! ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/17/aapl-a-busy-week-ahead-earnings-preview/85152/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Drug Candidate Presents New Data</title>
		<link>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706</link>
		<comments>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706#comments</comments>
		<pubDate>Wed, 21 Sep 2011 18:08:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83706</guid>
		<description><![CDATA[Merck (MRK) recently presented new clinical and pre-clinical data on its phase III pipeline candidate, odanacatib. Odanacatib is an investigational cathepsin K (cat-K) inhibitor which is being developed for the treatment of osteoporosis in post-menopausal women. Results were presented from a phase IIb clinical study extending to five years. Merck said that postmenopausal women being treated with odanacatib 50 mg weekly continuously for five years experienced an increase in bone mass density (BMD) at the lumbar spine (11.9% increase from baseline), femoral neck (9.8% increase from baseline), hip trochanter (10.9% increase from baseline), and total hip (8.5% increase from baseline). However, adverse and serious adverse experiences were higher in the odanacatib treatment group. Adverse experiences and serious adverse experiences were 89% and 22%, respectively in the odanacatib arm, compared to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692</link>
		<comments>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692#comments</comments>
		<pubDate>Wed, 21 Sep 2011 14:56:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83692</guid>
		<description><![CDATA[We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines based on therapeutic classes. These include: gastrointestinal, cardiovascular, respiratory and inflammation, oncology, neuroscience, infection and other. The company’s key products include Crestor (cholesterol management); Nexium (acid reflux); Seroquel (schizophrenia and bipolar mania); Atacand (hypertension and symptomatic heart failure), Arimidex (breast cancer), Zoladex (prostate and breast cancer) and Symbicort (asthma). We are impressed by the performance of lead drug Crestor which is primarily responsible for AstraZeneca being one of the leading players in the global cardiovascular market. The US launch of Brilinta (ticagrelor) for the reduction of the rate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Data Presented at European Association for the Study of Diabetes</title>
		<link>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265</link>
		<comments>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265#comments</comments>
		<pubDate>Mon, 19 Sep 2011 20:38:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83265</guid>
		<description><![CDATA[Novo Nordisk (NVO) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at an early stage in diabetes treatment of patients with type II diabetes, who had not received any treatment before or previously received only one oral anti-diabetic drug (OAD), led to greater improvements in glycaemic control than those who had been dosed two or more OAD’s. The second trial showed that when type II diabetes patients switched from oral treatment with Merck’s (MRK) Januvia to injectable Victoza (once daily) experienced increased treatment satisfaction as well as significant reductions in blood glucose and body weight. We remind investors that in June this year, Novo Nordisk had presented data from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387</link>
		<comments>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387#comments</comments>
		<pubDate>Thu, 01 Sep 2011 16:55:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82387</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. In August 2011, Alkermes disclosed financial results for the first quarter of fiscal 2012. Alkermes suffered a net loss (excluding special items but including stock-based compensation expense) of $0.04 per share which compared favorably with the year-ago loss of $0.14 per share. The Zacks Consensus Estimate was a loss of $0.11 per share. The narrower year-over-year loss was attributable to higher revenues recorded in the reported quarter. The lead product at Alkermes is Risperdal Consta for the treatment of schizophrenia and bipolar disorder. The drug is marketed worldwide by Johnson ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMLN) Amylin Pharmaceuticals Loss Narrows on Lower Costs</title>
		<link>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027</link>
		<comments>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:23:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CMC]]></category>
		<category><![CDATA[Commercial Metals Company]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80027</guid>
		<description><![CDATA[Amylin Pharmaceuticals (AMLN) reported a net loss of 21 cents per share in the second quarter of 2011, a penny wider than the Zacks Consensus Estimate but well below the year-ago loss of 28 cents. Despite a decline in revenues, year-over-year loss declined due to lower expenses. Second quarter revenues declined 3.8% to $158.1 million. Revenues, however, exceeded the Zacks Consensus Estimate of $156 million. Quarterly Details Total revenues for the quarter declined mainly due to lower net product sales. Quarterly revenues consisted of $154.8 million in product sales (down 4.8%) and $3.3 million in collaborative revenues, which consist of the amortization of upfront fees received under the company&#8217;s collaboration agreements with Eli Lilly (LLY) and Takeda. Product revenues comprised $129 million in sales of Byetta (exenatide) and $25.8 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/amln-amylin-pharmaceuticals-loss-narrows-on-lower-costs/80027/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) 2011 Second Quarter Earnings Preview &#8211; Detailed</title>
		<link>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251</link>
		<comments>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251#comments</comments>
		<pubDate>Mon, 18 Jul 2011 21:09:50 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[8x8 Inc]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[ABB]]></category>
		<category><![CDATA[ABB Limited]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Acacia Research Corporation]]></category>
		<category><![CDATA[Acme Packet Inc]]></category>
		<category><![CDATA[ACTG]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Air Products & Chemicals Inc.]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALB]]></category>
		<category><![CDATA[Albemarle Corporation]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Altera Corporation]]></category>
		<category><![CDATA[ALTR]]></category>
		<category><![CDATA[Altria Group Inc.]]></category>
		<category><![CDATA[ALV]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AmeriServ Financial Inc]]></category>
		<category><![CDATA[Amphenol Corporation]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR Corporation]]></category>
		<category><![CDATA[AMSG]]></category>
		<category><![CDATA[AmSurg Corporation]]></category>
		<category><![CDATA[AMTD]]></category>
		<category><![CDATA[AO Smith Corporation]]></category>
		<category><![CDATA[AOS]]></category>
		<category><![CDATA[APD]]></category>
		<category><![CDATA[APH]]></category>
		<category><![CDATA[APKT]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AptarGroup Inc.]]></category>
		<category><![CDATA[ARB]]></category>
		<category><![CDATA[Arbitron Inc]]></category>
		<category><![CDATA[ASBC]]></category>
		<category><![CDATA[ASR]]></category>
		<category><![CDATA[ASRV]]></category>
		<category><![CDATA[Associated Banc-Corp]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[AT Cross Company]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATMI]]></category>
		<category><![CDATA[ATMI Inc.]]></category>
		<category><![CDATA[ATR]]></category>
		<category><![CDATA[ATX]]></category>
		<category><![CDATA[Autoliv Inc.]]></category>
		<category><![CDATA[AVID]]></category>
		<category><![CDATA[Avid Technology Inc]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Badger Meter Inc]]></category>
		<category><![CDATA[BancFirst Corporation]]></category>
		<category><![CDATA[Banco Latinoamericano de Exportaciones SA]]></category>
		<category><![CDATA[Bancorp Rhode Island Inc]]></category>
		<category><![CDATA[BANF]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Banner Corporation]]></category>
		<category><![CDATA[BANR]]></category>
		<category><![CDATA[BARI]]></category>
		<category><![CDATA[BAS]]></category>
		<category><![CDATA[Basic Energy Services Inc.]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[BB & T Corporation]]></category>
		<category><![CDATA[BBT]]></category>
		<category><![CDATA[BJ's Restaurants Inc.]]></category>
		<category><![CDATA[BJRI]]></category>
		<category><![CDATA[BK]]></category>
		<category><![CDATA[BlackRock Inc.]]></category>
		<category><![CDATA[BLDR]]></category>
		<category><![CDATA[BLK]]></category>
		<category><![CDATA[BLX]]></category>
		<category><![CDATA[BMI]]></category>
		<category><![CDATA[BOOT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BPOP]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[BTU]]></category>
		<category><![CDATA[Builders FirstSource Inc]]></category>
		<category><![CDATA[BX]]></category>
		<category><![CDATA[CA]]></category>
		<category><![CDATA[Ca Technologies]]></category>
		<category><![CDATA[CAKE]]></category>
		<category><![CDATA[Cardinal Financial Corporation]]></category>
		<category><![CDATA[Cash America International Inc]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Cathay General Bancorp]]></category>
		<category><![CDATA[CATY]]></category>
		<category><![CDATA[CB]]></category>
		<category><![CDATA[CBE]]></category>
		<category><![CDATA[CBI]]></category>
		<category><![CDATA[CCK]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Celanese Corporation]]></category>
		<category><![CDATA[Celestica Inc.]]></category>
		<category><![CDATA[Cemex S.A.B. de C.V.]]></category>
		<category><![CDATA[Central Valley Community Bancorp]]></category>
		<category><![CDATA[Cepheid]]></category>
		<category><![CDATA[CFNL]]></category>
		<category><![CDATA[Charles Schwab Corporation]]></category>
		<category><![CDATA[Check Point Software Technologies Limited]]></category>
		<category><![CDATA[Chicago Bridge & Iron Company N.V.]]></category>
		<category><![CDATA[Chipotle Mexican Grill Inc.]]></category>
		<category><![CDATA[CHKP]]></category>
		<category><![CDATA[Cintas Corporation]]></category>
		<category><![CDATA[Cirrus Logic Inc.]]></category>
		<category><![CDATA[City National Corporation]]></category>
		<category><![CDATA[CLB]]></category>
		<category><![CDATA[CLS]]></category>
		<category><![CDATA[CMA]]></category>
		<category><![CDATA[CMCO]]></category>
		<category><![CDATA[CMG]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[CoBiz Financial Inc]]></category>
		<category><![CDATA[COBZ]]></category>
		<category><![CDATA[Coca-Cola FEMSA S.A.B de CV]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[COHU]]></category>
		<category><![CDATA[Cohu Inc]]></category>
		<category><![CDATA[COL]]></category>
		<category><![CDATA[Columbus Mckinnon Corporation]]></category>
		<category><![CDATA[Comerica Incorporated]]></category>
		<category><![CDATA[Complete Production Services Inc]]></category>
		<category><![CDATA[Compuware Corporation]]></category>
		<category><![CDATA[Cooper Industries Limited]]></category>
		<category><![CDATA[Core Laboratories NV]]></category>
		<category><![CDATA[Covanta Holding Corporation]]></category>
		<category><![CDATA[CPHD]]></category>
		<category><![CDATA[CPWR]]></category>
		<category><![CDATA[CPX]]></category>
		<category><![CDATA[Crown Holdings Inc.]]></category>
		<category><![CDATA[CRUS]]></category>
		<category><![CDATA[CSH]]></category>
		<category><![CDATA[CSX]]></category>
		<category><![CDATA[CSX Corporation]]></category>
		<category><![CDATA[CTAS]]></category>
		<category><![CDATA[CVA]]></category>
		<category><![CDATA[CVB Financial Corporation]]></category>
		<category><![CDATA[CVBF]]></category>
		<category><![CDATA[CVCY]]></category>
		<category><![CDATA[CX]]></category>
		<category><![CDATA[CY]]></category>
		<category><![CDATA[Cymer Inc.]]></category>
		<category><![CDATA[CYMI]]></category>
		<category><![CDATA[CYN]]></category>
		<category><![CDATA[Cypress Semiconductor Corporation]]></category>
		<category><![CDATA[CYT]]></category>
		<category><![CDATA[Cytec Industries Inc.]]></category>
		<category><![CDATA[DAL]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[Datalink Corporation]]></category>
		<category><![CDATA[Delta Air Lines Inc.]]></category>
		<category><![CDATA[DGII]]></category>
		<category><![CDATA[DGX]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[Diamond Offshore Drilling Inc]]></category>
		<category><![CDATA[Digi International Inc.]]></category>
		<category><![CDATA[DO]]></category>
		<category><![CDATA[DOV]]></category>
		<category><![CDATA[Dover Corporation]]></category>
		<category><![CDATA[DTLK]]></category>
		<category><![CDATA[E*TRADE Financial Corporation]]></category>
		<category><![CDATA[Eagle Bancorp Inc]]></category>
		<category><![CDATA[East West Bancorp Inc]]></category>
		<category><![CDATA[Eastern Virginia Bankshares Inc]]></category>
		<category><![CDATA[EastGroup Properties Inc]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[ECA]]></category>
		<category><![CDATA[EDR]]></category>
		<category><![CDATA[EDU]]></category>
		<category><![CDATA[Education Realty Trust Inc]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EFII]]></category>
		<category><![CDATA[EGBN]]></category>
		<category><![CDATA[EGHT]]></category>
		<category><![CDATA[EGP]]></category>
		<category><![CDATA[Electronics for Imaging Inc.]]></category>
		<category><![CDATA[ELGX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELS]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[Encana Corporation]]></category>
		<category><![CDATA[Endologix Inc]]></category>
		<category><![CDATA[Entegris Inc]]></category>
		<category><![CDATA[ENTG]]></category>
		<category><![CDATA[Equity Lifestyles Properties Inc]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[ESI]]></category>
		<category><![CDATA[ETFC]]></category>
		<category><![CDATA[EVBS]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[EWBC]]></category>
		<category><![CDATA[EXPO]]></category>
		<category><![CDATA[Exponent Inc.]]></category>
		<category><![CDATA[EZCORP Inc.]]></category>
		<category><![CDATA[EZPW]]></category>
		<category><![CDATA[F5 Networks Inc.]]></category>
		<category><![CDATA[FCFS]]></category>
		<category><![CDATA[FCX]]></category>
		<category><![CDATA[FFIV]]></category>
		<category><![CDATA[Fidelity National Information Services Inc]]></category>
		<category><![CDATA[Fifth Third Bancorp]]></category>
		<category><![CDATA[First Cash Financial Services Inc]]></category>
		<category><![CDATA[First Niagara Financial Group Inc]]></category>
		<category><![CDATA[FIS]]></category>
		<category><![CDATA[FITB]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[FLIR]]></category>
		<category><![CDATA[FLIR Systems Inc]]></category>
		<category><![CDATA[FMX]]></category>
		<category><![CDATA[FNFG]]></category>
		<category><![CDATA[Fomento Economico Mexicano S.a.b De C.v.]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[Forward Air Corporation]]></category>
		<category><![CDATA[Freeport-McMoRan Copper & Gold Inc]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[FULT]]></category>
		<category><![CDATA[Fulton Financial Corporation]]></category>
		<category><![CDATA[FWRD]]></category>
		<category><![CDATA[Gannett Company Inc]]></category>
		<category><![CDATA[Gardner Denver Inc.]]></category>
		<category><![CDATA[GCI]]></category>
		<category><![CDATA[GDI]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[Gentex Corporation]]></category>
		<category><![CDATA[GLF]]></category>
		<category><![CDATA[Glimcher Realty Trust]]></category>
		<category><![CDATA[Global Payments Inc]]></category>
		<category><![CDATA[GNTX]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[Goodrich Corporation]]></category>
		<category><![CDATA[GPN]]></category>
		<category><![CDATA[GR]]></category>
		<category><![CDATA[GRT]]></category>
		<category><![CDATA[Grupo Aeroportuario Centro Norte S.A. de C.V.]]></category>
		<category><![CDATA[Grupo Aeroportuario Del Sureste SA de CV]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Gulfmark Offshore Inc.]]></category>
		<category><![CDATA[GWW]]></category>
		<category><![CDATA[HAFC]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hancock Holding Company]]></category>
		<category><![CDATA[Hanesbrands Inc.]]></category>
		<category><![CDATA[Hanmi Financial Corporation]]></category>
		<category><![CDATA[Harley-Davidson Inc.]]></category>
		<category><![CDATA[HAS]]></category>
		<category><![CDATA[Hasbro Inc.]]></category>
		<category><![CDATA[HBAN]]></category>
		<category><![CDATA[HBHC]]></category>
		<category><![CDATA[HBI]]></category>
		<category><![CDATA[Healthways Inc]]></category>
		<category><![CDATA[Heartland Express Inc]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[HITT]]></category>
		<category><![CDATA[Hittite Microwave Corporation]]></category>
		<category><![CDATA[HNI]]></category>
		<category><![CDATA[HNI Corporation]]></category>
		<category><![CDATA[HOG]]></category>
		<category><![CDATA[HOMB]]></category>
		<category><![CDATA[Home Bancshares Inc (Conway AR)]]></category>
		<category><![CDATA[HON]]></category>
		<category><![CDATA[Honeywell International Inc.]]></category>
		<category><![CDATA[Host Hotels & Resorts Inc.]]></category>
		<category><![CDATA[HST]]></category>
		<category><![CDATA[HTLD]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[Huntington Bancshares Inc]]></category>
		<category><![CDATA[HWAY]]></category>
		<category><![CDATA[IBKR]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[ICLR]]></category>
		<category><![CDATA[ICON plc]]></category>
		<category><![CDATA[ICU Medical Inc]]></category>
		<category><![CDATA[ICUI]]></category>
		<category><![CDATA[IDEX Corporation]]></category>
		<category><![CDATA[IDEXX Laboratories Inc.]]></category>
		<category><![CDATA[IDXX]]></category>
		<category><![CDATA[IEX]]></category>
		<category><![CDATA[IIIN]]></category>
		<category><![CDATA[INFA]]></category>
		<category><![CDATA[Infinera Corporation]]></category>
		<category><![CDATA[INFN]]></category>
		<category><![CDATA[Informatica Corporation]]></category>
		<category><![CDATA[Ingersoll-Rand Company Limited]]></category>
		<category><![CDATA[Insteel Industries Inc.]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[Interactive Brokers Group Inc]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[IR]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[ITT Educational Services Inc.]]></category>
		<category><![CDATA[Ixia]]></category>
		<category><![CDATA[JAKK]]></category>
		<category><![CDATA[JAKKS Pacific Inc.]]></category>
		<category><![CDATA[Janus Capital Group Inc.]]></category>
		<category><![CDATA[JCI]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JNS]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Johnson Controls Inc.]]></category>
		<category><![CDATA[Kansas City Southern]]></category>
		<category><![CDATA[Kayne Anderson Energy Development Company]]></category>
		<category><![CDATA[KED]]></category>
		<category><![CDATA[KEY]]></category>
		<category><![CDATA[KeyCorp]]></category>
		<category><![CDATA[Kinder Morgan Energy Partners LP]]></category>
		<category><![CDATA[Kinder Morgan Management LLC]]></category>
		<category><![CDATA[KMP]]></category>
		<category><![CDATA[KMR]]></category>
		<category><![CDATA[KNL]]></category>
		<category><![CDATA[Knoll Inc.]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[KOF]]></category>
		<category><![CDATA[KSU]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[Lacrosse Footwear Inc.]]></category>
		<category><![CDATA[Landstar System Inc.]]></category>
		<category><![CDATA[Lare Holdings Inc]]></category>
		<category><![CDATA[LaSalle Hotel Properties]]></category>
		<category><![CDATA[Lattice Semiconductor Corporation]]></category>
		<category><![CDATA[LCC]]></category>
		<category><![CDATA[LECO]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[LHO]]></category>
		<category><![CDATA[Life Time Fitness Inc.]]></category>
		<category><![CDATA[Lincoln Electric Holdings]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[LNCR]]></category>
		<category><![CDATA[LSCC]]></category>
		<category><![CDATA[LSTR]]></category>
		<category><![CDATA[LTM]]></category>
		<category><![CDATA[LUFK]]></category>
		<category><![CDATA[Lufkin Industries Inc.]]></category>
		<category><![CDATA[M&T Bank Corporation]]></category>
		<category><![CDATA[MAN]]></category>
		<category><![CDATA[MANH]]></category>
		<category><![CDATA[Manhattan Associates Inc.]]></category>
		<category><![CDATA[Manpower Inc.]]></category>
		<category><![CDATA[Marten Transport Limited]]></category>
		<category><![CDATA[Matthews International Corporation]]></category>
		<category><![CDATA[MATW]]></category>
		<category><![CDATA[Mb Financial Inc]]></category>
		<category><![CDATA[MBFI]]></category>
		<category><![CDATA[MBWM]]></category>
		<category><![CDATA[MCBI]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[McMoRan Exploration Company]]></category>
		<category><![CDATA[MCRI]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Mellanox Technologies Limited]]></category>
		<category><![CDATA[Mercantile Bank Corporation]]></category>
		<category><![CDATA[Meridian Bioscience Inc.]]></category>
		<category><![CDATA[Merit Medical Systems Inc]]></category>
		<category><![CDATA[Metrocorp Bancshares Inc.]]></category>
		<category><![CDATA[MGIC Investment Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MKS Instruments Inc.]]></category>
		<category><![CDATA[MKSI]]></category>
		<category><![CDATA[MLNX]]></category>
		<category><![CDATA[MMR]]></category>
		<category><![CDATA[MMSI]]></category>
		<category><![CDATA[MNRO]]></category>
		<category><![CDATA[MO]]></category>
		<category><![CDATA[MOH]]></category>
		<category><![CDATA[Molina Healthcare Inc.]]></category>
		<category><![CDATA[Monarch Casino & Resort Inc.]]></category>
		<category><![CDATA[Monro Muffler Brake Inc.]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MOS]]></category>
		<category><![CDATA[Mosaic Company]]></category>
		<category><![CDATA[MOSY]]></category>
		<category><![CDATA[MoSys Inc]]></category>
		<category><![CDATA[MRTN]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[MTB]]></category>
		<category><![CDATA[MTG]]></category>
		<category><![CDATA[MYE]]></category>
		<category><![CDATA[Myers Industries Inc.]]></category>
		<category><![CDATA[NAFC]]></category>
		<category><![CDATA[Nash FInch Company]]></category>
		<category><![CDATA[NCR]]></category>
		<category><![CDATA[NCR Corporation]]></category>
		<category><![CDATA[NE]]></category>
		<category><![CDATA[NetScout Systems Inc]]></category>
		<category><![CDATA[New Oriental Education & Technology Group]]></category>
		<category><![CDATA[New York Community Bancorp Inc]]></category>
		<category><![CDATA[Newfield Exploration Company]]></category>
		<category><![CDATA[NFX]]></category>
		<category><![CDATA[Noble Corporation]]></category>
		<category><![CDATA[NOK]]></category>
		<category><![CDATA[Nokia Corporation]]></category>
		<category><![CDATA[Northern Trust Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NTCT]]></category>
		<category><![CDATA[NTRS]]></category>
		<category><![CDATA[Nucor Corporation]]></category>
		<category><![CDATA[NUE]]></category>
		<category><![CDATA[NVE Corporation]]></category>
		<category><![CDATA[NVEC]]></category>
		<category><![CDATA[NVR]]></category>
		<category><![CDATA[NVR Inc.]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[NYB]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[OceanFirst Financial Corporation]]></category>
		<category><![CDATA[OCFC]]></category>
		<category><![CDATA[OFG]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[Olin Corporation]]></category>
		<category><![CDATA[OLN]]></category>
		<category><![CDATA[OMAB]]></category>
		<category><![CDATA[OMC]]></category>
		<category><![CDATA[Omnicom Group Inc.]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[Oriental Financial Group Inc.]]></category>
		<category><![CDATA[Pacific Continental Corporation]]></category>
		<category><![CDATA[Packaging Corporation of America]]></category>
		<category><![CDATA[PAG]]></category>
		<category><![CDATA[Park National Corporation]]></category>
		<category><![CDATA[PBCT]]></category>
		<category><![CDATA[PCBK]]></category>
		<category><![CDATA[PCP]]></category>
		<category><![CDATA[PDS]]></category>
		<category><![CDATA[Peabody Energy Corporation]]></category>
		<category><![CDATA[PENN]]></category>
		<category><![CDATA[Penn National Gaming Inc.]]></category>
		<category><![CDATA[Penske Automotive Group Inc.]]></category>
		<category><![CDATA[Peoples United Financial Inc]]></category>
		<category><![CDATA[PEP]]></category>
		<category><![CDATA[Pepsico Inc.]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>
		<category><![CDATA[PGI]]></category>
		<category><![CDATA[Philip Morris International Inc]]></category>
		<category><![CDATA[PII]]></category>
		<category><![CDATA[Pinnacle Financial Partners Inc]]></category>
		<category><![CDATA[Piper Jaffray Companies]]></category>
		<category><![CDATA[PJC]]></category>
		<category><![CDATA[PKG]]></category>
		<category><![CDATA[Platinum Underwriters Holdings Limited]]></category>
		<category><![CDATA[PLCM]]></category>
		<category><![CDATA[Plexus Corporation]]></category>
		<category><![CDATA[PLXS]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[PMC-Sierra Inc.]]></category>
		<category><![CDATA[PMCS]]></category>
		<category><![CDATA[PNC]]></category>
		<category><![CDATA[PNC Financial Services Group Inc]]></category>
		<category><![CDATA[PNFP]]></category>
		<category><![CDATA[Polaris Industries Inc.]]></category>
		<category><![CDATA[Polycom Inc.]]></category>
		<category><![CDATA[POOL]]></category>
		<category><![CDATA[Pool Corp]]></category>
		<category><![CDATA[Popular Inc]]></category>
		<category><![CDATA[PPG]]></category>
		<category><![CDATA[PPG Industries Inc.]]></category>
		<category><![CDATA[Precision Castparts Corporation]]></category>
		<category><![CDATA[Precision Drilling Trust]]></category>
		<category><![CDATA[Premiere Global Services Inc.]]></category>
		<category><![CDATA[PRK]]></category>
		<category><![CDATA[Prosperity Bancshares Inc.]]></category>
		<category><![CDATA[PRSP]]></category>
		<category><![CDATA[PTP]]></category>
		<category><![CDATA[QCOM]]></category>
		<category><![CDATA[QUALCOMM Inc]]></category>
		<category><![CDATA[Quest Diagnostics Inc.]]></category>
		<category><![CDATA[RAI]]></category>
		<category><![CDATA[Raymond James Financial Inc.]]></category>
		<category><![CDATA[Renaissance Learning Inc.]]></category>
		<category><![CDATA[Renasant Corporation]]></category>
		<category><![CDATA[Reynolds American Inc.]]></category>
		<category><![CDATA[RHI]]></category>
		<category><![CDATA[Riverbed Technology Inc.]]></category>
		<category><![CDATA[RJF]]></category>
		<category><![CDATA[RLI]]></category>
		<category><![CDATA[RLI Corporation]]></category>
		<category><![CDATA[RLRN]]></category>
		<category><![CDATA[RNST]]></category>
		<category><![CDATA[Robert Half International Inc.]]></category>
		<category><![CDATA[Rockwell Collins Inc.]]></category>
		<category><![CDATA[RRR]]></category>
		<category><![CDATA[RSC Holdings Inc.]]></category>
		<category><![CDATA[RT]]></category>
		<category><![CDATA[Ruby Tuesday Inc.]]></category>
		<category><![CDATA[RVBD]]></category>
		<category><![CDATA[SABA]]></category>
		<category><![CDATA[Saba Software Inc.]]></category>
		<category><![CDATA[Safeway Inc.]]></category>
		<category><![CDATA[SanDisk Corporation]]></category>
		<category><![CDATA[Sandy Spring Bancorp Inc]]></category>
		<category><![CDATA[SASR]]></category>
		<category><![CDATA[SBIB]]></category>
		<category><![CDATA[Schiff Nutrition International Inc]]></category>
		<category><![CDATA[SCHL]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[Scholastic Corporation]]></category>
		<category><![CDATA[SCHW]]></category>
		<category><![CDATA[SCSS]]></category>
		<category><![CDATA[Seagate Technology]]></category>
		<category><![CDATA[SEI Investments Company]]></category>
		<category><![CDATA[SEIC]]></category>
		<category><![CDATA[Select Comfort Corporation]]></category>
		<category><![CDATA[Sensient Technologies Corporation]]></category>
		<category><![CDATA[SFG]]></category>
		<category><![CDATA[SFNC]]></category>
		<category><![CDATA[Sherwin-Williams Company]]></category>
		<category><![CDATA[SHW]]></category>
		<category><![CDATA[Simmons First National Corporation]]></category>
		<category><![CDATA[Skyworks Solutions Inc.]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SLM]]></category>
		<category><![CDATA[Slm Corporation]]></category>
		<category><![CDATA[SNA]]></category>
		<category><![CDATA[Snap-on Inc.]]></category>
		<category><![CDATA[SNDK]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[StanCorp Financial Group Inc.]]></category>
		<category><![CDATA[Stanley Black & Decker]]></category>
		<category><![CDATA[Stanley Furniture Company Inc]]></category>
		<category><![CDATA[State Street Corporation]]></category>
		<category><![CDATA[Steel Dynamics Inc.]]></category>
		<category><![CDATA[Sterling Bancshares Inc]]></category>
		<category><![CDATA[STI]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[STLD]]></category>
		<category><![CDATA[STLY]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[STT]]></category>
		<category><![CDATA[STX]]></category>
		<category><![CDATA[SunTrust Banks Inc.]]></category>
		<category><![CDATA[SWK]]></category>
		<category><![CDATA[SWKS]]></category>
		<category><![CDATA[SWY]]></category>
		<category><![CDATA[SXT]]></category>
		<category><![CDATA[SY Bancorp Inc.]]></category>
		<category><![CDATA[SYBT]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[Taubman Centers Inc.]]></category>
		<category><![CDATA[TAYC]]></category>
		<category><![CDATA[Taylor Capital Group Inc]]></category>
		<category><![CDATA[TBBK]]></category>
		<category><![CDATA[TCB]]></category>
		<category><![CDATA[TCBI]]></category>
		<category><![CDATA[TCF Financial Corporation]]></category>
		<category><![CDATA[TCO]]></category>
		<category><![CDATA[TD AMERITRADE Holding Corporation]]></category>
		<category><![CDATA[TEL]]></category>
		<category><![CDATA[Temple-Inland Inc.]]></category>
		<category><![CDATA[Terex Corporation]]></category>
		<category><![CDATA[TESS]]></category>
		<category><![CDATA[TESSCO Technologies Inc.]]></category>
		<category><![CDATA[TEX]]></category>
		<category><![CDATA[Texas Capital BancShares Inc.]]></category>
		<category><![CDATA[Textron Inc.]]></category>
		<category><![CDATA[The Bancorp Inc]]></category>
		<category><![CDATA[The Bank of New York Mellon Corporation]]></category>
		<category><![CDATA[The Blackstone Group]]></category>
		<category><![CDATA[The Cheesecake Factory Incorporated]]></category>
		<category><![CDATA[The Chubb Corporation]]></category>
		<category><![CDATA[The Coca-Cola Company]]></category>
		<category><![CDATA[The New York Times Company]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[Thomas & Betts Corporation]]></category>
		<category><![CDATA[TIN]]></category>
		<category><![CDATA[TNB]]></category>
		<category><![CDATA[Tractor Supply Company]]></category>
		<category><![CDATA[TRIB]]></category>
		<category><![CDATA[Trinity Biotech plc]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[TSCO]]></category>
		<category><![CDATA[TXT]]></category>
		<category><![CDATA[Tyco Electronics Limited]]></category>
		<category><![CDATA[UAL]]></category>
		<category><![CDATA[UBNK]]></category>
		<category><![CDATA[Ultratech Inc.]]></category>
		<category><![CDATA[UMPQ]]></category>
		<category><![CDATA[Umpqua Holdings Corporation]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[Union Pacific Corporation]]></category>
		<category><![CDATA[United Continental Holdings]]></category>
		<category><![CDATA[United Financial Bancorp]]></category>
		<category><![CDATA[United Rentals Inc]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[Unitedhealth Group Inc.]]></category>
		<category><![CDATA[UNP]]></category>
		<category><![CDATA[URI]]></category>
		<category><![CDATA[US Airways Group Inc.]]></category>
		<category><![CDATA[Us Bancorp]]></category>
		<category><![CDATA[USB]]></category>
		<category><![CDATA[UTEK]]></category>
		<category><![CDATA[UTX]]></category>
		<category><![CDATA[VCBI]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>
		<category><![CDATA[Virginia Commerce Bancorp Inc]]></category>
		<category><![CDATA[Vitran Corp Inc]]></category>
		<category><![CDATA[VIVO]]></category>
		<category><![CDATA[VMW]]></category>
		<category><![CDATA[VMware Inc.]]></category>
		<category><![CDATA[VTNC]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[W.W. Grainger Inc]]></category>
		<category><![CDATA[WABC]]></category>
		<category><![CDATA[WAL]]></category>
		<category><![CDATA[Waste Connections Inc.]]></category>
		<category><![CDATA[Watsco Inc.]]></category>
		<category><![CDATA[WCC]]></category>
		<category><![CDATA[WCN]]></category>
		<category><![CDATA[WDC]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WERN]]></category>
		<category><![CDATA[Werner Enterprises Inc.]]></category>
		<category><![CDATA[WESCO International Inc.]]></category>
		<category><![CDATA[Westamerica BanCorporation]]></category>
		<category><![CDATA[Westell Technologies Inc]]></category>
		<category><![CDATA[Western Alliance Bancorporation]]></category>
		<category><![CDATA[Western Digital Corporation]]></category>
		<category><![CDATA[Westwood Holdings Group Inc]]></category>
		<category><![CDATA[WFC]]></category>
		<category><![CDATA[WHG]]></category>
		<category><![CDATA[Whirlpool Corporation]]></category>
		<category><![CDATA[WHR]]></category>
		<category><![CDATA[Wipro Limited]]></category>
		<category><![CDATA[WIT]]></category>
		<category><![CDATA[WNI]]></category>
		<category><![CDATA[WNS]]></category>
		<category><![CDATA[WNS (Holdings) Limited]]></category>
		<category><![CDATA[WSO]]></category>
		<category><![CDATA[WSTL]]></category>
		<category><![CDATA[WYNN]]></category>
		<category><![CDATA[Wynn Resorts Limited]]></category>
		<category><![CDATA[Xerox Corporation]]></category>
		<category><![CDATA[Xilinx Inc.]]></category>
		<category><![CDATA[XLNX]]></category>
		<category><![CDATA[XRX]]></category>
		<category><![CDATA[XXIA]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>
		<category><![CDATA[ZION]]></category>
		<category><![CDATA[Zions BanCorporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79251</guid>
		<description><![CDATA[Earnings Preview 7/15/11 Second quarter earnings season is now under way, but things really start to move into high gear next week. There will be 348 firms reporting, and 108 of those are in the S&#38;P 500. By next Friday we should have a very good handle on how the overall earnings season will go. The firms reporting this week are sort of like a who&#8217;s who of U.S. industry including: Apple (AAPL), American Express (AXP), Bank of America (BAC), Caterpillar (CAT), General Electric (GE), International Business Machines (IBM), Intel (INTC), McDonald&#8217;s (MCD), Schlumberger (SLB) and Verizon (VZ). That is an interesting cross section of U.S. business. We have a relatively light economic data calendar, so earnings should be front and center, along with the sovereign debt situations on both ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/18/aapl-2011-second-quarter-earnings-preview-detailed/79251/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SHPGY) Shire Entangled in Legal Dispute</title>
		<link>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527</link>
		<comments>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527#comments</comments>
		<pubDate>Thu, 07 Jul 2011 16:59:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78527</guid>
		<description><![CDATA[The legal tussle between Shire (SHPGY), Sandoz, Inc. &#8212; the generic arm of Novartis (NVS) and Amneal Pharmaceuticals &#8212; intensified with Shire filing a patent infringement case against the two companies relating to Vyvanse. Vyvanse is indicated for treating patients suffering from attention deficit hyperactive disorder (ADHD). Amneal and Sandoz have filed abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (FDA) to market generic versions of Vyvanse at all doses. ADHD refers to a neurobiological disorder that is often hereditary in nature. The disease gives way to lack of attention and often results in impulsiveness and hyperactivity. We note that the marketing exclusivity for Vyvanse expires in February 2012, under the Hatch-Waxman Act. By filing patent infringement lawsuits Shire has ensured a 30-month stay by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/shpgy-shire-entangled-in-legal-dispute/78527/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly Provides Research and Development Update</title>
		<link>http://www.stockbloghub.com/2011/07/05/lly-eli-lilly-provides-research-and-development-update/78330</link>
		<comments>http://www.stockbloghub.com/2011/07/05/lly-eli-lilly-provides-research-and-development-update/78330#comments</comments>
		<pubDate>Tue, 05 Jul 2011 16:34:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78330</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently provided an insight into its research and development (R&#38;D) plans and mid-term guidance at a meeting with the investment community. The company outlined its plans for combating the impact of the patent expiration of several key products. About $7 billion of revenues will be lost to generic competition due to the loss of exclusivity of products like Zyprexa, Cymbalta, Evista, and Gemzar. Pipeline to Drive Long-Term Growth Eli Lilly intends to continue spending significantly on its pipeline. The company expects to spend about 25% of revenues on its R&#38;D efforts.  Eli Lilly currently has about 70 candidates in its pipeline including 33 candidates in phase II and III stages of development. The company expects to launch several candidates through 2017 and is on track ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/lly-eli-lilly-provides-research-and-development-update/78330/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Presents Late Stage Degludec Data</title>
		<link>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249</link>
		<comments>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:06:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78249</guid>
		<description><![CDATA[Recently, Novo Nordisk (NVO) presented data from late stage trials, which showed that its ultra-long acting insulin Degludec lowered blood glucose levels with significantly reduced risk of hypoglycemia (low blood sugar) versus Sanofi Aventis’(SNY) Lantus in patients with type II diabetes. Novo Nordisk presented data from two, late stage, 52-week clinical trials, one in patients with type I and the other in victims of type II diabetes. These data were presented at the American Diabetes Association. Degludec particularly reduced nocturnal hypoglycemia (night-time episodes of excessively low blood sugar) versus Lantus in patients with type I or type II diabetes. Nocturnal hypoglycemia is highly feared by diabetics, and hence a reduced threat of it represents a real commercial edge for Degludec. Apart from the two studies, Novo Nordisk also presented data ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/nvo-novo-nordisk-presents-late-stage-degludec-data/78249/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229</link>
		<comments>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:31:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78229</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32).  ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole).  Alkermes intends to present complete data from the study at an upcoming medical conference. The double-blind, randomized, placebo-controlled 20-week study evaluated the safety, tolerability and pharmacokinetics of ALKS 9070 (once-monthly) at 3 doses in patients suffering from chronic, stable schizophrenia. Data from the study revealed that the candidate was generally well tolerated at all  doses and achieved therapeutically relevant plasma concentrations of Abilify. The pharmacokinetic profile backed the once-monthly dosing of ALKS 9070. Encouraged by the positive results, the company intends to commence a pivotal development program for the candidate by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
